Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of escalating oral doses of BI 201335 in treatment-naïve hepatitis C patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 201335

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C, Pharmacokinetics | Phase 2 | Status: COMPLETED | Results posted: 2015-07-07